Literature DB >> 10205260

A worldwide assessment of the frequency of suicide, suicide attempts, or psychiatric hospitalization after predictive testing for Huntington disease.

E W Almqvist1, M Bloch, R Brinkman, D Craufurd, M R Hayden.   

Abstract

Prior to the implementation of predictive-testing programs for Huntington disease (HD), significant concern was raised concerning the likelihood of catastrophic events (CEs), particularly in those persons receiving an increased-risk result. We have investigated the frequency of CEs-that is, suicide, suicide attempt, and psychiatric hospitalization-after an HD predictive-testing result, through questionnaires sent to predictive-testing centers worldwide. A total of 44 persons (0.97%) in a cohort of 4,527 test participants had a CE: 5 successful suicides, 21 suicide attempts, and 18 hospitalizations for psychiatric reasons. All persons committing suicide had signs of HD, whereas 11 (52.4%) of 21 persons attempting suicide and 8 (44.4%) of 18 who had a psychiatric hospitalization were symptomatic. A total of 11 (84.6%) of 13 asymptomatic persons who experienced a CE during the first year after HD predictive testing received an increased-risk result. Factors associated with an increased risk of a CE included (a) a psychiatric history </=5 years prior to testing and (b) unemployed status. The frequency of CEs did not differ between those persons receiving results of predictive testing through linkage analysis in whom there was only changes in direction of risk and those persons receiving definitive results after analysis for the mutation underlying HD. These findings provide insights into the frequency, associated factors, and timing of CEs in a worldwide cohort of persons receiving predictive-testing results and, as such, highlight persons for whom ongoing support may be beneficial.

Entities:  

Keywords:  Death and Euthanasia; Empirical Approach; Genetics and Reproduction

Mesh:

Year:  1999        PMID: 10205260      PMCID: PMC1377865          DOI: 10.1086/302374

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  43 in total

1.  Stigmatization of carrier status: social implications of heterozygote genetic screening programs.

Authors:  R H Kenen; R M Schmidt
Journal:  Am J Public Health       Date:  1978-11       Impact factor: 9.308

2.  Huntington's chorea in Northamptonshire.

Authors:  J E Oliver
Journal:  Br J Psychiatry       Date:  1970-03       Impact factor: 9.319

3.  At risk for Huntington's disease: who should know what and when?

Authors:  A Rosenfeld
Journal:  Hastings Cent Rep       Date:  1984-06       Impact factor: 2.683

Review 4.  Unemployment and suicidal behaviour: a review of the literature.

Authors:  S Platt
Journal:  Soc Sci Med       Date:  1984       Impact factor: 4.634

5.  Social perspectives in Huntington's chorea.

Authors:  M R Hayden; R Ehrlich; H Parker; S J Ferera
Journal:  S Afr Med J       Date:  1980-08-02

6.  Increased rate of suicide among patients with Huntington's disease.

Authors:  M Schoenfeld; R H Myers; L A Cupples; B Berkman; D S Sax; E Clark
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-12       Impact factor: 10.154

7.  Inheritance of torsion dystonia in Jews.

Authors:  R Eldridge
Journal:  Ann Neurol       Date:  1981-08       Impact factor: 10.422

8.  Attitudes toward presymptomatic testing in Huntington disease.

Authors:  C Mastromauro; R H Myers; B Berkman
Journal:  Am J Med Genet       Date:  1987-02

9.  Attitudes of persons at risk for Huntington disease toward predictive testing.

Authors:  S Kessler; T Field; L Worth; H Mosbarger
Journal:  Am J Med Genet       Date:  1987-02

10.  Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk.

Authors:  L A Farrer
Journal:  Am J Med Genet       Date:  1986-06
View more
  45 in total

1.  Huntington's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-05       Impact factor: 3.598

2.  The psychological dimension of informed consent: dissonance processes in genetic testing.

Authors:  Sonja Grover
Journal:  J Genet Couns       Date:  2003-10       Impact factor: 2.537

3.  Prenatal whole genome sequencing: just because we can, should we?

Authors:  Greer Donley; Sara Chandros Hull; Benjamin E Berkman
Journal:  Hastings Cent Rep       Date:  2012-06-20       Impact factor: 2.683

4.  Psychological functioning before predictive testing for Huntington's disease: the role of the parental disease, risk perception, and subjective proximity of the disease.

Authors:  M Decruyenaere; G Evers-Kiebooms; A Boogaerts; J J Cassiman; T Cloostermans; K Demyttenaere; R Dom; J P Fryns
Journal:  J Med Genet       Date:  1999-12       Impact factor: 6.318

Review 5.  Huntington's disease genetics.

Authors:  Richard H Myers
Journal:  NeuroRx       Date:  2004-04

6.  Depression and suicidal ideation after predictive testing for Huntington's disease: a two-year follow-up study.

Authors:  Maria U Larsson; Mary A Luszcz; The-Hung Bui; Tarja-Brita Robins Wahlin
Journal:  J Genet Couns       Date:  2006-10       Impact factor: 2.537

Review 7.  Why tell asymptomatic children of the risk of an adult-onset disease in the family but not test them for it?

Authors:  P J Malpas
Journal:  J Med Ethics       Date:  2006-11       Impact factor: 2.903

8.  Neural bases of dysphoria in early Huntington's disease.

Authors:  Sergio Paradiso; Beth M Turner; Jane S Paulsen; Ricardo Jorge; Laura L Boles Ponto; Robert G Robinson
Journal:  Psychiatry Res       Date:  2008-01-15       Impact factor: 3.222

9.  What to Do with a Second Chance in Life? Long-Term Experiences of Non-carriers of Huntington's Disease.

Authors:  Elisabeth Winnberg; Ulrika Winnberg; Lilian Pohlkamp; Anette Hagberg
Journal:  J Genet Couns       Date:  2018-04-07       Impact factor: 2.537

Review 10.  Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.

Authors:  J Scott Roberts; Wendy R Uhlmann
Journal:  Prog Neurobiol       Date:  2013-04-09       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.